Trial · NCT06118398
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
NCT06118398, Unknown, Feng Jinzhou
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders. Trials, record NCT06118398. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06118398
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
- NCT number
- NCT06118398
- Status
- Unknown
- Enrollment
- 24 participants, estimated
- Lead sponsor
- Feng Jinzhou
- Conditions
- Neuromyelitis Optica, Efgartigimod
- Interventions
- Intravenous methylprednisolone (IVMP) and Efgartigimod, IVMP
- First posted
- 2023-11-07
- Last updated
- 2023-11-07
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Expanded Disability Status Scale (EDSS) score from baseline. | 1 month | Change in Expanded Disability Status Scale (EDSS) score from baseline to 1 month after treatment (EDSS: Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). |
| Secondary | Change in Expanded Disability Status Scale (EDSS) score from baseline. | 3 months, 6 months | Change in Expanded Disability Status Scale (EDSS) score from baseline to 3 months, 6 months after treatment (EDSS: Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). |
| Secondary | Percentage of Participants with Disability Improvement | 1 month, 3 months, 6 months | Disability improvement is defined as a reduction in EDSS score of: A) ≥1.0 point from the baseline EDSS score when the baseline score was ≤5.5; B) ≥0.5 point when the baseline EDSS score \> 5.5(EDSS: Minimum Score 1, Maximum score 10, higher scores mean a worse outcome). |
| Secondary | Change in modified Rankin score (mRS) from baseline. | 1 month, 3 months, 6 months | Change in modified Rankin score (mRS) from baseline at 1 month 1, 3 month 3 and 6 month (mRS: Minimum Score 0, Maximum score 6, higher scores mean a worse outcome). |
| Secondary | Time to first relapse | 6 months | |
| Secondary | Number of New, and/or Enlarging T2 Hyperintense Lesions Detected by Magnetic Resonance Imaging (MRI) | 6 months | Number of New, and/or Enlarging T2 Hyperintense Lesions Detected by Magnetic Resonance Imaging (MRI) at the last visit. |
| Secondary | Change in timed 25 Foot Walk Test from baseline. | 1 month, 3 months, 6 months | Change in time taken to complete the timed 25 Foot Walk Test from baseline. |
| Secondary | Number of NMOSD attacked during follow-up | 6 months | Number of NMOSD treatment related to acute attack during follow-up. |
| Secondary | Change in serum GFAP levels from baseline | 1 month, 6 months | Change in serum GFAP levels from baseline to the last visit. |
| Secondary | Change in AQP4-ab titres from baseline | 1month, 6 months | Change in AQP4-ab titres from baseline to the last visit |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06118398
GET https://conductscience.org/api/trials/v1/NCT06118398/registered